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A B S T R A C T
Recurrent seizures may occur in up to 11% of HIV positive patients. The aetiology of the seizures includes
opportunistic infections, neoplasia, HIV itself, metabolic derangements and drugs. Apart from treating
the cause of the seizures, the challenge is to use the appropriate anticonvulsant drug (AED) to avoid
potentially adverse drug–drug interactions in patientswho are on concurrent highly active antiretroviral
therapy (HAART). Initial recommendations were that the newer AEDs should preferably be used because
of their simpler pharmacokinetics.
We report on our experience with the use sodium valproate (SV) in eight patients who were on
concurrent HAART. There were twomales and six females with a mean age of 34.1 years. The mean dose
of SV was 1075 mg per day. Seizure control was excellent, the CD4 count improved and there was
successful viral suppression in all patients.
This small study showed that SV was safe and effective. It is also relatively inexpensive compared to
the newer AEDs – an important consideration in resource poor settings.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Recurrent seizures represent an important clinical manifesta-
tion of neurological disease in HIV infection. Frequency rates of 3–
11% have been reported in hospital based studies of HIV infected
individuals.1–6 The aetiology of seizures in HIV-infected indivi-
duals include opportunistic infections, neoplasia, HIV itself,
metabolic derangements and drugs.1–6
Apart from identifying and treating the underlying cause of the
seizures, the challenge is to use the appropriate anticonvulsant
(AED) in patients who are on highly active anti-retroviral therapy
(HAART). Protein binding and metabolism via cytochrome P450
system could lead to adverse drug–drug interaction and loss of
viral suppression. Initial recommendations were that the newer
AEDs such as gabapentin, levetiracetam and tiagabine should
preferably be used as they have simpler pharmacokinetics than the
older AEDs such as phenytoin and carbamazepine.7,8 The same
authors advised caution with the use of valproate/valproic acid
(SV/VA) as, in vitro studies suggested that this drug promoted viral
replication.9,10* Corresponding author at: Department of Neurology, Inkosi Albert Luthuli
Central Hospital, Private Bag X03, Mayville 4058, South Africa.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.09.009We report on the clinical and laboratory ﬁndings of eight
patients who were on concurrent sodium valproate (SV) and
HAART.
2. Methods and case studies
HIV positive patients on HAART who developed new onset
seizures were recruited for the study. Patients or their guardians
who gave consent were included in the study. Exclusion criteria
included known allergy to SV, hepatic enzymes greater than 10
times the upper limit of normal, a prothrombin time that was 5 or
more seconds than the control value, and pregnancy. The study
was approved by the Bioethics Committee of the University of
KwaZulu-Natal.
All patients underwent a complete clinical examination. At
baseline the following routine blood investigations were done: full
blood count (FBC), urea and electrolytes (U&E), liver function tests
(LFTs), glucose, calcium, magnesium, phosphate, international
normalised ratio (INR), rapid plasma reagin (RPR) and antinuclear
factor (ANF). CD4 counts and viral loads weremeasured at baseline
and at approximately 2–6 month intervals. All patients had a chest
radiograph and either a CT or MRI scan of the brain. If indicated,
cerebrospinal ﬂuid was subjected to routine chemistry, microsco-
py, bacterial and fungal culture, viral polymerase chain reaction
studies, cryptococcal antigen and cytological examination.
According to the South African national guidelines for HAART,
all except one patient were on either regimen 1a (Stavudine,vier Ltd. All rights reserved.
Table 1
Clinical and radiological data. Patient 4 was followed up as part of another trial using a different regimen – tenofovir, emtricitabine and efavirenz. 1a= stavudine, lamivudine
and efavirenz. 1b= stavudine, lamivudine and nevirapine.
Patient Age and
gender
HAART
regimen
Duration of
HAART (months)
Aetiology of
seizures
Radiological
ﬁndings
Daily dose of sodium
valproate (mg)
Seizure
control
1 45 (M) 1a 12 Uncertain MRI normal 600 Excellent
2 42 (F) 1b Started at
seizure onset
Tuberculomata MRI – multiple enhancing
surface lesions
1200 Occasional seizure
3 36 (F) 1b 8 Uncertain CT normal 900 Improved
4 39 (F) TRU/EFV 13 Old TB CT calciﬁed granuloma 900 Excellent
5 12 (F) 1a 1 Drug related CT normal 900 Improved
6 27 (F) 1b 2 Uncertain CT normal 1200 Improved
7 39 (M) 1a 1 Old TB CT calciﬁed granuloma 900 Excellent
8 33 (F) 1a 1 TBM MRI enhancing lesions 2000 Excellent
Y. Yacoob et al. / Seizure 20 (2011) 80–82 81Lamivudine and Efavirenz) or 1b (Stavudine, Lamivudine and
Nevirapine).
3. Results
The clinical and radiological data are summarized in Table 1.
The duration of follow up after institution of AEDs, the CD4 counts
and viral loads are summarized in Table 2. There were two males
and six females with a mean age of 34.1 years (range 12–45). The
duration of HAART therapy ranged from 0 to 13 months prior to
commencements of SV. The mean daily dose of SV was 1075 mg
(range 600–2000 mg). The duration of follow up after initiation of
SV ranged from two to thirty nine (mean of 15) months. The
aetiology of seizures was tuberculosis in two patients. Patient 2
with brain tuberculomata presented with seizures and was
commenced on ARVs at seizure onset. Patient 8 was diagnosed
with TB meningitis a month after ARV initiation. An IRIS
phenomenon was considered. Both patients were given standard
4 drug antituberculous therapy together with a month of
prednisone at 40 mg daily. Patient 1 had lamotrigine (25 mg bd)
and patient 8 had gabapentin (300 mg tds) added to their
treatment. Four became seizure free, one had the occasional
seizure, two had a single seizure each in 6 months and 1 had a
seizure in 2 months of follow up. The mean CD4 count at baseline
was 187 with a range from 2 to 550. The CD4 count improved in all
patients. The viral load was suppressed in all patients.
4. Discussion
Potential adverse drug-disease and drug–drug interactions in
HIV infected individuals have been reported in isolated caseTable 2
The duration of follow up on AEDs and HAART, the CD4 counts and viral loads.
Patient 4 was part of another trial where the viral load cut off value was
<400 copies/ml. ND=not done due to technical difﬁculties. Patient 5 had a baseline
CD4 value >200 as the CD4 percentage rather than absolute CD4 value is used in
paediatric ARV clinics as a criteria for initiation of ARVs. Patient 7was re-instated on
ARVs following a 6 month default and the baseline CD4 represents the point of re-
initiation.
Patient Duration of
follow up
(months)
CD4 counts VL (copies/ml)
Baseline Latest Baseline Latest
1 36 2 270 ND <25
2 32 20 523 9300 <25
3 9 130 418 <25 <25
4 18 183 247 12,900 <400
5 6 550 875 ND <25
6 2 44 328 7900 <25
7 6 480 688 230 <25
8 6 88 292 ND <25studies. As many as 14% of HIV seropositive patients on phenytoin
had hypersensitivity reactions.1 Drugs such as phenytoin, carba-
mazepine and phenobarbitonemay increase themetabolism of the
protease inhibitors (PI) and result in loss of viral suppression.11
Conversely, inhibition of the CYP 450 enzyme system by the PIs
may lead to toxic levels of phenytoin and carbamazepine.12 Factors
such as these, as well as the concern that SV/VA may increase viral
replication9,10 led to the earlier recommendation that the older
AEDs should be avoided in HIV seropositive patients who were on
HAART.
Although there are no large prospective studies examining
drug–drug interactions, the earlier concern about SV/VA has not
been conﬁrmed by more recent studies. Maggi and Helman13 did
not ﬁnd increased viral loads in six patients taking valproate. In
fact a proof of concept study suggested that the addition of valproic
acid to HAART may be beneﬁcial in depleting latent HIV
infection.14 Although, this concept was not conﬁrmed,15,16 these
studies did show that SV/VA was safe.
Our small study conﬁrms the efﬁcacy and safety of SV/VA in HIV
seropositive patients on HAART. In all patients there was a rise in
CD4 counts and adequate viral suppression. None of our patients
was on zidovudinewhose bioavailability (and hence side effects) is
increased in the presence of SV/VA.14 Nor was any patients on PIs.
The data on PIs and SV/VA is scanty but close monitoring is
advised.17
5. Conclusion
There is little information about the combination of HAART and
newer AEDs. Locatelli et al.18 studied seven patients on HAART and
Leviteracetam. The combinationwas safe and effective. Despite the
initial call for use of the newer AEDs for patients onHAART because
of their (AEDs) simpler pharmacokinetics, the data on the newer
AEDs is limited. There is the additional aspect of the cost of the
newer AEDs – an important consideration in resource poor
settings. Currently, there is increasing evidence that SV/VA can
be used safely and effectively in patients who are on HAART.
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